ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > 4-1BB

4-1BB

概要

Name:Tumor necrosis factor receptor superfamily member 9
Target Synonym:TNFRSF9,T-cell antigen ILA,ILA,TNF Receptor Superfamily Member 9,T-Cell Antigen 4-1BB Homolog,4-1BB Ligand Receptor,CD137 Antigen,CDw137,CD137,Interleukin-Activated Receptor, Homolog Of Mouse Ly63,Tumor Necrosis Factor Receptor Superfamily, Member 9,Tumor Necrosis Factor Receptor Superfamily Member 9,Induced By Lymphocyte Activation (ILA),Homolog Of Mouse 4-1BB,Receptor Protein 4-1BB,T Cell Antigen ILA,4-1BB
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:71
Lastest Research Phase:Phase 3 Clinical

製品リスト製品比較と製品注文

製造番号 種類 製品説明 構造 純度 特徴
41B-H53H3 Human Human 4-1BB / TNFRSF9 Protein, His Tag (MALS verified)
41B-H53H3-structure
41B-H53H3-sds
CHEK-ATP038 Human HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line
41B-H82F8 Human Biotinylated Human 4-1BB / TNFRSF9 Protein, Fc,Avitag™ (MALS verified)
41B-H82F8-structure
41B-H82F8-sds
41B-H52H9 Human Human 4-1BB / TNFRSF9 (24-86) Protein, His Tag
41B-H52H9-structure
41B-H52H9-sds
41B-H82E9 Human Biotinylated Human 4-1BB / TNFRSF9 (24-86) Protein, His,Avitag™
41B-H82E9-structure
41B-H82E9-sds
41B-C82E9 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque 4-1BB / TNFRSF9 Protein, Avitag™,His Tag (MALS verified)
41B-C82E9-structure
41B-C82E9-sds
41B-M82E8 Mouse Biotinylated Mouse 4-1BB / TNFRSF9 (24-211) Protein, Avitag™,His Tag (MALS verified)
41B-M82E8-structure
41B-M82E8-sds
41B-C5253 Canine Canine 4-1BB / TNFRSF9 Protein, Fc Tag (MALS verified)
41B-C5253-structure
41B-C5253-sds
41B-H82E4 Human Biotinylated Human 4-1BB / TNFRSF9 (87-186) Protein, His,Avitag™ (MALS verified)
41B-H82E4-structure
41B-H82E4-sds
41B-H5253 Human Human 4-1BB / TNFRSF9 (87-186) Protein, Fc Tag (MALS verified)
41B-H5253-structure
41B-H5253-sds
41B-R52H3 Rat Rat 4-1BB / TNFRSF9 Protein, His Tag (MALS verified)
41B-R52H3-structure
41B-R52H3-sds
41B-H52Hc Human Human 4-1BB / TNFRSF9 Protein, His Tag
41B-H52Hc-structure
41B-H52Hc-sds
41B-H82E6 Human Biotinylated Human 4-1BB / TNFRSF9 Protein, His,Avitag™(MALS verified)
41B-H82E6-structure
41B-H82E6-sds
41B-R52H9 Rabbit Rabbit 4-1BB / TNFRSF9 Protein, His Tag (MALS verified)
41B-R52H9-structure
41B-R52H9-sds
41B-H5256 Human Human 4-1BB / TNFRSF9 Protein, Mouse IgG2a Fc Tag, low endotoxin
41B-H5256-structure
41B-H5256-sds
41B-M52H7 Mouse Mouse 4-1BB / TNFRSF9 Protein, His Tag
41B-M52H7-structure
41B-M52H7-sds
41B-M5258 Mouse Mouse 4-1BB /TNFRSF9 Protein, Fc Tag (MALS verified)
41B-M5258-structure
41B-M5258-sds
41B-C52H4 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque 4-1BB / TNFRSF9 Protein, His Tag (MALS verified)
41B-C52H4-structure
41B-C52H4-sds
41B-H5258 Human Human 4-1BB / TNFRSF9 Protein, Fc Tag (MALS verified)
41B-H5258-structure
41B-H5258-sds
ACRO Quality

カスタマーレビュー

Synonym Name

TNFRSF9,4-1BB,CD137,CDw137,ILA

Background

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Clinical and Translational Updates

相関分子

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
STA-551 STA-551 Phase 1 Clinical Chugai Pharmaceutical Co Ltd Solid tumours Details
PM-1003 PM1003 Phase 2 Clinical Biotheus Inc Solid tumours Details
QL-301 QL-301 Phase 1 Clinical Neoplasms Details
Cedarizumab Phase 1 Clinical Therawisdom Biopharma Co Ltd Solid tumours; Carcinoma, Transitional Cell; Melanoma Details
ZG-033 ZG033 Phase 1 Clinical Neoplasms Details
DF-003(Dingfu Biotarget) DF-003 Phase 1 Clinical Dingfu Biotarget Co Ltd Solid tumours; Lymphoma, Non-Hodgkin Details
QL-1806 QL-1806 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
Ensomafusp alfa RG-6076 Phase 1 Clinical F. Hoffmann-La Roche Ltd Details
HOT-1030 HOT-1030 Phase 1 Clinical Huabo Biopharm Co Ltd Solid tumours Details
TJ-L14B ABL-503; TJ-L14B/ABL503; ABL503 I-Mab Biopharma Co Ltd Details
RO-7122290 RO-7122290; RG-7827 F. Hoffmann-La Roche Ltd Details
QLF31907 QLF31907; QLF-31907 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
Ori-Bs-001 Ori-Bs-001 Phase 1 Clinical Solid tumours Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details
IMB-071703 IMB071703; IMB-071703 Phase 1 Clinical Beijng Immunoah Pharma Tech Co Ltd Solid tumours Details
Humanized CART Directed Against BCMA ARI-0002h Phase 2 Clinical Instituto De Salud Carlos Iii Multiple Myeloma Details
PRS-344 PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 Phase 2 Clinical Pieris Pharmaceuticals Inc, Laboratoires Servier Solid tumours Details
ADG-106 ADG-106 Phase 2 Clinical Adagene (Suzhou) Ltd Solid tumours; Lymphoma, Non-Hodgkin Details
HBM-7008 HBM7008; HBM-7008; R-7008 Phase 1 Clinical Harbour Biomed Solid tumours Details
Cinrebafusp alfa PRS-343 Phase 2 Clinical Pieris Pharmaceuticals Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms Details
Delolimogene mupadenorepvec LOAd-703 Phase 2 Clinical Uppsala University, Lokon Pharma Biliary Tract Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma Details
ATOR-1017 ATOR-1017 Phase 1 Clinical Alligator Bioscience Ab Solid tumours; Neoplasms Details
LBL-024 LBL024; LBL-024 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours; Neoplasms Details
FS-222 FS-222 Phase 1 Clinical F-star Beta Ltd Neoplasms; Neoplasm Metastasis Details
LVGN-6051 LVGN-6051 Phase 2 Clinical Lyvgen Biopharma(HK)Ltd Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Neoplasms; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis Details
INBRX-105 ES101; INBRX-105 Phase 1 Clinical Inhibrx Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Esophageal adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
MCLA-145 MCLA-145 Phase 1 Clinical Incyte Corp, Merus Nv Solid tumours; Neoplasms Details
FS-120 FS-120 Phase 1 Clinical F-Star Neoplasms; Neoplasm Metastasis Details
Urelumab BMS-66513; BMS-663513 Phase 2 Clinical Bristol-Myers Squibb Company Lymphoma, B-Cell; Head and Neck Neoplasms; Solid tumours; Leukemia; Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Skin Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Gliosarcoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
BNA-035 BNA-035 Phase 1 Clinical Binacea Pharma Inc Solid tumours Details
CART-38(University of Pennsylvania) CART-38 Phase 1 Clinical University Of Pennsylvania Multiple Myeloma; Leukemia, Myeloid, Acute Details
GNC-035 quadr-specific antibody(baili) GNC-035 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer Details
AGEN-2373 AGEN-2373 Phase 1 Clinical Agenus Inc Neoplasms Details
Acasunlimab PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 Phase 2 Clinical Genmab A/S, Biontech Se Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
HK-010 HK010; HK-010 Phase 1 Clinical Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd Neoplasms Details
FTL-001 FTL001; FTL-001 Phase 1 Clinical Xikang (Wuhan) Biomedicine Co Ltd, Sound(Chengdu)Biopharmacauticals Co Ltd Solid tumours Details
PE-0116 PE-0116 Phase 1 Clinical Shanghai HyaMab Biotech Co Ltd Solid tumours Details
PM-1032 PM1032; PM-1032 Phase 1 Clinical Biotheus Inc, Shanghai Genechem Co Ltd Neoplasms Details
BT-7480 BT-7480 Phase 2 Clinical Bicycle Therapeutics Solid tumours; Neoplasms Details
ATG-101 ATG-101 Phase 1 Clinical Antengene Corporation Co Ltd Solid tumours; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Neoplasm Metastasis Details
YH-004 YH-004 Phase 1 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin Details
Utomilumab PF-05082566; PF-2566; PF-5082566 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Lymphoma, Mantle-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Oropharyngeal Neoplasms; Colorectal Neoplasms; Lymphoma, Follicular; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, B-Cell; Triple Negative Breast Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Head and Neck Neoplasms; Ovarian Neoplasms; Solid tumours Details
Tecaginlimab BNT-312; GEN-1042 Phase 2 Clinical Genmab A/S Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Peripheral Nervous System Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma Details
ADG-206 ADG-206 Phase 1 Clinical Adagene (Suzhou) Ltd Neoplasms Details
DSP-107 DSP-107; KAHR-107 Phase 2 Clinical Kahr Medical Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
CTX-471 CTX-471 Phase 1 Clinical Compass Therapeutics LLC Solid tumours; Head and Neck Neoplasms; Small Cell Lung Carcinoma; Mesothelioma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Emfizatamab GNC-038 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Details
SGN-BB228 SGN-BB228 Phase 1 Clinical Seagen Inc Skin Melanoma; Pancreatic Neoplasms; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
IBI-319 IBI-319 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
HLX-35 HLX-35 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
TJ-CD4B TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-CD4B/ABL111; TJ-033721 Phase 1 Clinical I-Mab Biopharma Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis Details
EU-101 EU-101; NOV-1801 Phase 2 Clinical Eutilex Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ND-021 ND-021; NM21-1480; CS-2006; CS2006 Phase 2 Clinical Numab Therapeutics Ag, Cstone Pharmaceuticals Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MP-0310 MP-0310; AMG-506 Phase 1 Clinical Molecular Partners Ag, Amgen Inc Solid tumours Details

This web search service is supported by Google Inc.

totopphone